Efficacy in Alveolar Bone Regeneration With Autologous MSCs and Biomaterial in Comparison to Autologous Bone Grafting (Maxibone)
Randomized Controlled Clinical Trial to Assess the Efficacy of a Combination of Autologous Mesenchymal Stem Cells and Biomaterial in Jaw Bone Regeneration Prior to Dental Implant Placement in Comparison to Standard Autologous Bone Grafting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Kamal Mustafa, Professor
- Phone Number: +47 98497607
- Email: kamal.mustafa@uib.no
Study Contact Backup
- Name: Cecilie Gjerde, DDS
- Phone Number: +47 55 58 64 41
- Email: cecilie.gjerde@uib.no
Study Locations
-
-
-
Odense, Denmark, 5230
- Syddansk Universitet SDU (University Hospital of Southern Denmark)
-
-
-
-
-
Créteil, France, 94010
- Assistance Publique - Hôpitaux de Paris
-
Nantes, France, 44000
- CHU Nantes, Centre de Soins Dentaires
-
-
-
-
Hordaland
-
Bergen, Hordaland, Norway, 5009
- University of Bergen, Institute of Clonical Dentistry
-
-
-
-
-
Barcelona, Spain, 08195
- Universitat Internacional de Catalunya
-
-
Calle Fernando de Castro Rodriguez,
-
Madrid, Calle Fernando de Castro Rodriguez,, Spain, 28040
- Universidad Complutense de Madrid
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy, non smoking patients in need of dental implants in the upper or lower jaw, with loss in vertical height and less that 4 mm in lateral width.
Exclusion Criteria:
- General contraindications for dental and/or surgical treatments
- Contraindications for both bone marrow harvesting and bone grafts
- History of any malignant diseases
- Concurrent or previous radiotherapy of head and neck region
- History of contagious diseases (HIV, HTLV and/or syphilis seropositivity, hepatitis B or C infection)
- Uncontrolled diabetes mellitis, e.g. patients with diabetes not regulated with medications or diet. This will be verified based on patient's history and concurrent HbA1c levels (HbA1c > 53 mmol/mol).
- Inflammatory and autoimmune disease of the oral cavity.
- Concurrent or previous immunosuppressant, bisphosphonate or high dose corticosteroid therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control
The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.
|
Augmentation of the alveolar ridge with bone graft
|
|
Experimental: Test
Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate
|
Augmentation of alveolar ridge with MSC and biomaterial
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in bone width
Time Frame: 0-5 months
|
Changes in linear measurements of bone width measured by CBCT.Principal assessment is linear change in bone width 2 mm below alveolar crest measured by means of CBCT images from baseline to 5 months after the regenerative surgery, immediately prior to implant placement
|
0-5 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain postoperatively in the two different treatments
Time Frame: 21 months
|
Assessed by VAS scale, the scale goes from 0 to 100, 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable."
|
21 months
|
|
Radiological examination of bone volume
Time Frame: 21 months
|
To evaluate the formation of the new bone by assessing if it is possible to insert an implant in the reconstructed area 5 months after the grafting procedure.
This decision will be made based on radiological examination of bone volume by means of 3D CBCT images captured immediately prior to implant placement, 5-6 months after the regenerative surgery.
|
21 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mariano Sanz, Professor, Universidad Complutense de Madrid
- Principal Investigator: Else Marie Pinholt, Professor, Syddansk Universitet SDU (University Hospital of Southern Denmark)
- Principal Investigator: Federico Hernandez-Alfaroo, Professor, Universitat Internacional de Catalunya
- Principal Investigator: Alain Hoornaert, DDS, CHU Nantes, Centre de Soins Dentaires
- Principal Investigator: Frederik Gaultier, PhD/DDS, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
General Publications
- Gjerde C, Mustafa K, Hellem S, Rojewski M, Gjengedal H, Yassin MA, Feng X, Skaale S, Berge T, Rosen A, Shi XQ, Ahmed AB, Gjertsen BT, Schrezenmeier H, Layrolle P. Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. Stem Cell Res Ther. 2018 Aug 9;9(1):213. doi: 10.1186/s13287-018-0951-9.
- Rojewski MT, Lotfi R, Gjerde C, Mustafa K, Veronesi E, Ahmed AB, Wiesneth M, Korper S, Sensebe L, Layrolle P, Hellem S, Schrezenmeier H. Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. Cytotherapy. 2019 Apr;21(4):468-482. doi: 10.1016/j.jcyt.2019.03.001. Epub 2019 Mar 27.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018-001227-39 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.